GALT, US3632252025

MarketBeat cites USD 11.00 target for Galectin Therapeutics stock

Published on 10/20/2026 at 19:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galectin Therapeutics lost USD 9.18 million in the second quarter of 2026. Galectin Therapeutics stock costs EUR 3.09 on October 20, 2026.

Analyst target and results

MarketBeat reported a USD 11.00 consensus target and mixed ratings on October 16, 2026.
Galectin Therapeutics recorded a USD 9.18 million net loss in the second quarter of 2026.
Galectin Therapeutics stock costs EUR 3.09 at Lang & Schwarz on October 20, 2026 at 7:17 p.m. CEST.
The next earnings date is November 13, 2026.

GALT, US3632252025, Illustration mit AI erstellt.

MarketBeat reported on October 16, 2026 that Galectin Therapeutics had a consensus price target of USD 11.00, alongside one Buy, one Hold and one Sell rating. The company stock was trading at EUR 3.09 at Lang & Schwarz on October 20, 2026 at 7:17 p.m. CEST, after the Xetra close.

Analyst target meets mixed ratings

The USD 11.00 target was paired with a mixed analyst picture rather than a uniform view. MarketBeat said HC Wainwright had reiterated a Buy rating and a USD 11.00 target on June 23, 2026, while Zacks Research had upgraded its rating to Hold on August 11, 2026. Weiss Ratings reaffirmed a Sell rating on September 14, 2026.

Second-quarter loss remains central

Galectin Therapeutics reported a net loss of USD 9.18 million and basic earnings per share of minus USD 0.14 for the second quarter of 2026. The quarterly loss was USD 0.05 per share below the consensus estimate of minus USD 0.09, according to MarketBeat on October 16, 2026.

Price position and next date

Galectin Therapeutics had a market capitalization of USD 229.5 million on October 20, 2026. Its Nasdaq-listed stock had a 52-week range of USD 2.03 to USD 7.13 on October 19, 2026, while its year-to-date performance was minus 13.0 percent on October 16, 2026. Investing.com identifies Nasdaq as the primary exchange and confirms the ISIN.

The next earnings date is November 13, 2026, as listed by MetaCap. The date gives investors a defined point for the next update on the clinical-stage biotechnology company's cash use and development program.

Clinical pipeline keeps the focus

Galectin Therapeutics is developing belapectin, also known as GR-MD-02, as a treatment candidate for fibrotic liver disease and cancer. Its second-quarter loss and the November reporting date leave clinical progress and financing requirements as the main company-specific items for the next report.

At Lang & Schwarz, Galectin Therapeutics stock was trading at EUR 3.09 on October 20, 2026 at 7:17 p.m. CEST, after the Xetra close. The further course of trading is shown by the continuously updated real-time quote of Galectin Therapeutics stock.